All News 1 July, 2025Xinnate raises SEK 31 million in oversubscribed share issue 27 June, 2025New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD 23 May, 2025Xinnate announces successful FDA meeting for TCP-25 14 January, 2025Xinnate receives Orphan Drug Designation from US FDA for TCP-25 17 December, 2024Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm 27 September, 2024Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa 5 September, 2024Xinnate presents TCP-25 data at international dermatology congress 7 May, 2024Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa 18 March, 2024Xinnate completes Phase 1a/b study with TCP-25 7 February, 2024Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa 18 March, 2023Xinnate appoints Anna-Karin Lindqvist as new COO19 October, 2022Approved clinical trial application for BioC gel on complex wounds15 September, 2022Excellent results from phase I study shows that the BioC gel is safe and well tolerated.15 July, 2022Funding secured for the next step of BioC clinical plan1 July, 2022Xinnate is awarded a prestigious grant from the US Department of Defense25 March, 2022Approved clinical trial application for First in Human study on BioC gel20 August, 2021New publication: BioC-coated dressing shows promising effect on both infection and inflammation26 October, 2020Funding secured for the first clinical study of BioC wound gel11 October, 2020Xinnate has received a prestigious Swedish Research Council grant18 January, 2020Xinnate is looking for a Chief Operating Officer16 January, 2020Great interest for the STM article and coverage in Nature Reviews Drug Discovery8 January, 2020Breakthrough results published in Science Translational Medicine1 January, 2020A new article about BioC results from Lund University
